Items Tagged ‘Ovarian Cancer’

November 9th, 2016

Lynparza™ Clinical Trial Demonstrates Survival Benefit in Relapsed Ovarian Cancer

By

AstraZeneca has announced positive results from the Phase III SOLO-2 trial designed to determine the efficacy of LynparzaTM (olaparib) oral therapy for the maintenance treatment of platinum-sensitive relapsed, BRCA-mutated ovarian cancer.1 Results from the trial demonstrate a clinically-meaningful improvement in survival free of cancer progression. Importantly, the median time to cancer progression for Lynparza-treated patients […]

View full entry

Tags: AstraZeneca, BRACAnalysis CDx, brca, lynparza, News, olaprarib, Ovarian Cancer, PARP enzyme, Recurrent Ovarian Cancer, Stage II-IV Ovarian Cancer


October 31st, 2016

Update on PARP Inhibitors for Ovarian Cancer with BRCA Mutations

By

Each year in the United States, roughly 22,000 women are diagnosed with ovarian cancer and more than 15,000 die of the disease. Treatment for ovarian cancer commonly involves surgery and/or chemotherapy. Researchers continue to study new approaches for improving the outcomes of all women affected by ovarian cancer but progress has been slow. The PARP […]

View full entry

Tags: BRCA1, BRCA2, lynparza, News, niraparib, olaparib, Ovarian Cancer, PARP inhibitor, Recurrent Ovarian Cancer, Rucaparib, Stage I Ovarian Cancer, Stage II-IV Ovarian Cancer


October 20th, 2016

Tesaro Provides Real Benefit to Ovarian Cancer Patients

By

Patients with platinum-sensitive recurrent ovarian cancer showed significantly improved cancer-free survival with Tesaro (niraparib) in the first clinical trial directly comparing a poly(ADP)-ribose polymerase (PARP) inhibitor with chemotherapy. Tesaro improved cancer-free survival by 73% in patients with a BRCA mutation and by 55% in those without such mutations. The new data were presented at the […]

View full entry

Tags: 2016, BRCA mutation, ESMO, News, niraparib, Ovarian Cancer, parp, poly(ADP)-ribose polymerase, recurrent, Recurrent Ovarian Cancer, Stage II-IV Ovarian Cancer, Tesaro


October 6th, 2016

FDA Warns Against Ovarian Cancer Screening Tests

By

According to the US Food and Drug Administration (FDA) doctors and their patients should not use certain ovarian cancer screening tests because of inaccurate results. Screening tests are designed to detect cancer in its earliest stages when it is most treatable. Inaccurate tests however, can miss a cancer diagnosis when one is present or falsely […]

View full entry

Tags: false, Inaccurate results, News, Ovarian Cancer, prevention, screening, Screening/Prevention Ovarian Cancer, tests


September 6th, 2016

FDA Accepts Priority Review of Rucaparib For The Treatment Of Advanced Mutant BRCA Ovarian Cancer

By

The U.S. Food and Drug Administration (FDA) has accepted a New Drug Application (NDA) for accelerated approval of rucaparib and granted priority review status to the application for the treatment of advanced ovarian cancer in patients with deleterious BRCA-mutated cancers. Rucaparib was granted Breakthrough Therapy Designation by the FDA in April 2015. About Ovarian Cancer […]

View full entry

Tags: Breakthrough Therapy Designation, News, Ovarian Cancer, PARP1, PARP2, PARP3, Stage II-IV Ovarian Cancer


August 22nd, 2016

SGO, ASCO Issue New Guidelines for Ovarian Cancer Treatment

By

A new joint clinical practice guideline from the American Society of Clinical Oncology (ASCO) and the Society of Gynecologic Oncology (SGO) states that neoadjuvant chemotherapy (NACT) is the optimal first-line treatment for some women who have newly diagnosed advanced ovarian cancer. While the standard of care in this setting is primary cytoreductive surgery (PCS) followed […]

View full entry

Tags: advanced, asco, cytoreductive surgery, epithelial, metastatic, NACT, News, Ovarian Cancer, SGO, Stage II-IV Ovarian Cancer


July 13th, 2016

Niraparib Improves Progression-Free Survival in Ovarian Cancer

By

The PARP inhibitor niraparib improves the time to cancer progression among patients with recurrent ovarian cancer when used as maintenance therapy during platinum-based chemotherapy. Each year in the United States, approximately 22,000 women are diagnosed with ovarian cancer, and is the fifth most common cause of cancer-related deaths among women. Since there are no generalized […]

View full entry

Tags: BRCA1, BRCA2, News, niraparib, NOVA trial, Ovarian Cancer, PARP inhibitor, Recurrent Ovarian Cancer


May 25th, 2016

Counsyl Announces Major Oncology Expansion to Advance Genetic Screening for Cancer Risk

By

Counsyl launches oncology business unit, an expanded test to assess risk for inherited forms of cancer, and tools to improve genetic screening rates across the healthcare system Counsyl, a DNA testing and genetic counseling service, today announced its expansion into the oncology market, with a focus on advancing cancer risk screening and helping cancer prevention efforts. Counsyl’s […]

View full entry

Tags: asco, ASCO16, ASCO2016, BRCAtesting, breast, Breast Cancer, breastcancerawareness, colon, Colon Cancer, DNAtesting, genetic testing, inherited cancer screen


September 28th, 2015

Intraperitoneal Chemotherapy Underused in Ovarian Cancer

By

The use of intraperitoneal (IP) chemotherapy appears to be utilized in fewer than 50% of clinical practices, despite results indicating improved survival with its use in certain patients with ovarian cancer. These results were recently published in the Journal of Clinical Oncology. IP chemotherapy refers to chemotherapy that is delivered directly into the pelvis/abdominal area, […]

View full entry

Tags: intraperitoneal chemotherapy, IP, IV chemotherapy, News, Ovarian Cancer, Stage I Ovarian Cancer, Stage II-IV Ovarian Cancer


September 3rd, 2015

Ovarian Cancer survival Influenced by History of Oral Contraceptive Use

By

A history of oral contraceptive use and having at least one child increased longevity by nearly three years in patients diagnosed with ovarian cancer, according to a Roswell Park Cancer Institute (RPCI) study recently published online ahead of print in the International Journal of Gynecological Cancer. “Ovarian cancer is the fifth leading cause of death […]

View full entry

Tags: News, oral contraceptives, Ovarian Cancer


June 15th, 2015

Drug Rucaparib Promising in Pretreated BRCA-Positive Ovarian Cancer

By

The drug rucaparib appears active in women with recurrent BRCA-positive ovarian cancer that has progressed after previous treatment. These findings were presented at 2015 Annual Meeting of the American Society of Clinical Oncology (May 29–June 2, Chicago, Illinois) and published in the Journal of Clinical Oncology. Each year in the United States, roughly 22,000 women […]

View full entry

Tags: BCRA-positive ovarian cancer, News, Ovarian Cancer, PARP inhibitor, Recurrent Ovarian Cancer, Rucaparib


May 27th, 2015

AFCR-funded Scientists Discover New Drug Combination to Overcome Chemotherapy Resistance in Ovarian Cancer

By

A recent discovery of a new combinational treatment approach may help solve the notorious problem of chemotherapy resistance in ovarian cancer, increasing patient survival for one of the deadliest cancer types in the world.  This work was led by Wei Zhang, Ph.D., Professor at MD Anderson Cancer Center in the U.S. in collaboration with Guoyan […]

View full entry

Tags: Asian Fund for Cancer Research, chemotherapy resistance, combination treatment, miR-506, News, Ovarian Cancer


May 26th, 2015

Lynparza™

By

Class: Biological Therapy Generic Name: Olaparib Trade Name: Lynparza™ For which conditions is this drug approved? Lynparza is used treat women with advanced ovarian cancer who have: a) received previous treatment with three or more prior chemotherapy medicines or a combination of chemotherapy medicines; and b) have a certain type of abnormal inherited BRCA gene. […]

View full entry

Tags: Biological Therapy, Drug Dictionary, L, Ovarian Cancer, PARP inhibitor


May 26th, 2015

Olaparib

By

Class: Biological Therapy Generic Name: Olaparib Trade Name: Lynparza™ For which conditions is this drug approved? Lynparza is used treat women with advanced ovarian cancer who have: a) received previous treatment with three or more prior chemotherapy medicines or a combination of chemotherapy medicines; and b) have a certain type of abnormal inherited BRCA gene. […]

View full entry

Tags: Biological Therapy, Drug Dictionary, lynparza, O, Ovarian Cancer, PARP inhibitor


May 18th, 2015

Personalized Screening Test for Ovarian Cancer Potentially Game-Changing, says GlobalData

By

   LONDON, UK (GlobalData), 12 May 2015 – The encouraging recent results of a 14-year study by the UK Collaborative Trial of Ovarian Cancer Screening could herald a radical departure from the approach established by other screening tests for cancer, providing the final data is sufficiently conclusive, says an analyst with research and consulting firm […]

View full entry

Tags: CA-125, GlobalData, News, Ovarian Cancer, screening test, Screening/Prevention Ovarian Cancer